The Hypertension Optimal Treatment in Children with Chronic Kidney Disease study

Not Applicable

Completed

• Conditions: Chronic kidney disease; Urological and Genital Diseases

• Registration Number: ISRCTN25006406
• Lead Sponsor: Guy's and St. Thomas' NHS Foundation Trust (UK)

Brief Summary

2022 Results article in https://doi.org/10.1016/s2352-4642(22)00302-9 (added 29/11/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-08-16
• Study Completion: 2019-03-31
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

1. Aged 2 to 15 years
2. Chronic kidney disease with eGFR between 15-90 ml/min/1.73m2 for two consecutive measurements in the last 12 months
3. With or without anti-hypertensive/s medications (irrespective of recent change/s in antihypertensive therapy)
4. Subjects with average clinic systolic BP <50th percentile and on no antihypertensive medication will be eligible as ?CONTROL? subjects only
5. Other ?CONTROL? subjects will include children with normal renal function and blood pressure attending hospital for unrelated medical review or siblings of subjects with CKD
6. Male and female participants

Exclusion Criteria

1. Age <2 and >15 years
2. Subjects who have/had an arterio-venous fistulae
3. Subjects who have/had are on dialysis
4. Subjects who have/had a functioning kidney transplant
5. Patients with symptomatic BP or with past history of difficulty to control BP or
6. Patients in whom there is a clinical urgency to treat BP and inclusion in study may result inpossible delay of treatment
7. Patients with arrhythmia or clinical heart failure
8. Patients with known structural cardiac abnormality
9. Subjects on treatment with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) agents for treatment of proteinuria only or
10. Subjects who are likely to be of clinical concern following up or down titration of BP levels as described in ?Appendix 3?
11. Subjects who are unable or intolerant to performance of study measurements e.g. height, echo or PWV
12. Subjects who have/had intolerance to Angiotensin converting enzyme inhibitors (ACEi) drug/s or have any existing contraindications

Study & Design

• Study Type: Interventional
• Study Design: Not specified